期刊
EXPERT REVIEW OF VACCINES
卷 11, 期 11, 页码 1293-1303出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERV.12.108
关键词
adults; children; clinical trials; immunogenicity; influenza B; intranasal; quadrivalent live-attenuated influenza vaccine; safety
类别
资金
- MedImmune, LLC
Expert Rev. Vaccines 11(11), 1293-1303 (2012) Influenza B is responsible for significant morbidity in children and adults worldwide. For more than 25 years, two antigenically distinct lineages of influenza B viruses, B/Yamagata and B/Victoria, have cocirculated globally. Current influenza vaccine formulations are trivalent and contain two influenza subtype A strains (A/H1N1 and A/H3N2) but only one B strain. In a half of recent influenza seasons, the predominant circulating influenza B lineage was different from that contained in trivalent influenza vaccines. A quadrivalent live-attenuated influenza vaccine (Q/LAIV) that contains two B strains, one from each lineage, has been developed to help provide broad protection against influenza B. Q/LAIV was recently approved for use in the USA in eligible individuals 2-49 years of age. This review summarizes clinical trial data in support of Q/LAIV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据